CalciMedica Revenue and Competitors
Estimated Revenue & Valuation
- CalciMedica's estimated annual revenue is currently $2.3M per year.
- CalciMedica's estimated revenue per employee is $155,000
Employee Data
- CalciMedica has 15 Employees.
- CalciMedica grew their employee count by 15% last year.
CalciMedica's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Chief Regulatory Officer | Reveal Email/Phone |
4 | Chief Business Officer and Vice Chairman | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Senior Director Clinical Operations | Reveal Email/Phone |
7 | Sr. Director, Clinical Operations | Reveal Email/Phone |
8 | Executive Assistant/Office Manager | Reveal Email/Phone |
9 | President and COO | Reveal Email/Phone |
10 | General Counsel | Reveal Email/Phone |
CalciMedica Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is CalciMedica?
CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr. Stauderman’s work includes the discovery of the role of STIM1, which works in concert with Orai1 in the CRAC channels targeted by CalciMedica’s drugs. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications. It has also assembled a portfolio of patents and patent applications covering those compounds as well as different aspects of CRAC channel biology.
keywords:N/A
N/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in La Jolla
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.3M | 15 | N/A | N/A |
#2 | N/A | 16 | -16% | N/A |
#3 | $2.5M | 16 | 7% | N/A |
#4 | $2.6M | 16 | -47% | N/A |
#5 | $1.4M | 16 | 0% | N/A |